Myovant Sciences Ltd.
MYOVDelisted Mar 10, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001679082
Myovant Sciences Ltd. was delisted on Mar 10, 2023; its insiders filed their last Form 4 on Mar 10, 2023; 118 institutions reported holding it in 13F filings for Q4 2022, worth $1.12B in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 118
- Q4 2022, +24 vs. previous quarter
- 13F value
- $1.12B
- Reported value at the end of Q4 2022
- Superinvestors holding
- 0
- At the end of Q4 2022
Superinvestors holding MYOV, Q4 2022
No superinvestor reported holding MYOV at the end of Q4 2022.
Latest insider trades
Open-market purchases and sales by Myovant Sciences Ltd. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2023 (view filing)9:17 AM ET | Mar 10 | Same day | Sumitomo Pharma Co., Ltd. and 2 others10% Owner | PPurchase | +51.6M | $27.00 | +$1.39B | New position45.8M after | |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Lang MatthewGeneral Counsel & Corp. Secy. | SSale | −1.27K | $26.89 | −$34.2K | −0.4%354.3K after | |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Merendino LaurenChief Commercial Officer | SSale | −2.01K | $26.89 | −$54.0K | −1.2%169.5K after | |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Marek David CPrincipal Executive Officer | SSale | −8.04K | $26.89 | −$216.1K | −1.9%417.6K after | |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Arjona Ferreira Juan CamiloChief Medical Officer | SSale | −1.11K | $26.89 | −$29.8K | −0.4%246.7K after | |
| Jan 5, 2023 (view filing) | Jan 4 | 1 day | Arjona Ferreira Juan CamiloChief Medical Officer | SSale | −2.25K | $26.90 | −$60.6K | −0.9%247.8K after | |
| Jan 5, 2023 (view filing) | Jan 4 | 1 day | Lang MatthewGeneral Counsel & Corp. Secy. | SSale | −2.78K | $26.90 | −$74.8K | −0.8%355.6K after | |
| Dec 20, 2022 (view filing) | Dec 16 | 4 days | Mehra UneekPrincipal Financial Officer | SSale | −2.24K | $26.75 | −$59.9K | −1.1%202.7K after | |
| Oct 20, 2022 (view filing) | Oct 18 | 2 days | Merendino LaurenChief Commercial Officer | SSale | −1.70K | $25.20 | −$42.9K | −1.0%171.5K after | |
| Oct 20, 2022 (view filing) | Oct 18 | 2 days | Marek David CPrincipal Executive Officer | SSale | −11.2K | $25.20 | −$281.1K | −2.6%425.6K after |
Top 10 13F holders, Q4 2022
The largest institutional positions in Myovant Sciences Ltd. at the end of Q4 2022; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FIL Ltd | 8,624,543 | $232.5M | 0.28% | +8,624,543 | New |
| Bellevue Group AG | 5,910,639 | $159.4M | 2.11% | −2,0000.0% | Reduced |
| State Street Corp | 2,910,023 | $78.5M | 0.00% | +893,665+44.3% | Added |
| Goldman Sachs Group Inc | 2,420,659 | $65.3M | 0.02% | +1,929,497+392.8% | Added |
| Carlson Capital L P | 1,805,249 | $48.7M | 3.73% | +1,805,249 | New |
| CNH Partners LLC | 1,387,550 | $37.4M | 0.96% | +1,387,550 | New |
| Highland Capital Management Fund Advisors, L.P. | 1,338,030 | $36.1M | 2.81% | +1,338,030 | New |
| Alpine Associates Management Inc. | 1,307,785 | $35.3M | 1.61% | +1,307,785 | New |
| BlackRock Inc. | 1,182,942 | $31.9M | 0.00% | −3,588−0.3% | Reduced |
| Janus Henderson Group PLC | 1,177,158 | $31.7M | 0.02% | −2,776,683−70.2% | Reduced |